Ocular Toxicities Associated with Antibody-Dr...

Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics: Introduction: Where We Are; Where We’re Heading (0:00)First-Line Treatment of BRCA Wild-Type Disease (9:14)First-Line Treatment of BRCA-Mutant Disease (38:48)Novel Approaches (47:4 ...  Show more

Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics:Introduction (0:00)Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58)Contemporary Management of HER2-Positive Metastatic Breast Cancer — ...  Show more

Dr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers. 

NIH'S policies, programs, and research funding fill gaps in knowledge about women's health. Janine Austin Clayton, MD, of the NIH joins JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss key programs, policies, and scientific advances of the NIH that have i ...

Join experts Drs Kevin Kalinsky and Aditya Bardia as they discuss utilizing antibody-drug conjugates in clinic. What is currently available? What are the possible side effects? Tune in to find out. Relevant disclosures can be found with the episode show notes on Medscape (https:/ ...  Show more

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more